IP Verse

Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate - EP2508188B1

PatentPatent Analysis

EP2508188

ASTRAZENECA
Application Number
EP12153939A
Filing Date
Mar 21, 2008
Status
Granted And Under Opposition
Apr 7, 2023
Grant Date
May 10, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3045466B2
EP4175619B1
EP4175620B1

Bibliography

The patent EP2508188B1 was granted to Astrazeneca on May 10, 2023 following the initial filing on Mar 21, 2008 under the application number EP12153939A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUFeb 9, 2024ADMISSIBLE
GEDEON RICHTERFeb 9, 2024ADMISSIBLE
GENERICS UKFeb 9, 2024ADMISSIBLE
KRAUS & LEDERER PARTGMBBFeb 9, 2024ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBFeb 6, 2024ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents